NASDAQ:RAPP Rapport Therapeutics Q3 2026 Earnings Results & Report $25.47 +0.03 (+0.12%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more. Rapport Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.84 versus the -$1.20 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeBefore Market OpensConference Call7:00 AM ET Rapport Therapeutics EPS ResultsActual EPS-$0.84Consensus EPS -$1.20Beat/MissBeat by +$0.36One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersRapport Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rapport Therapeutics Q3 2026 Earnings FAQ Did Rapport Therapeutics beat earnings estimates for Q3 2026? Rapport Therapeutics (NASDAQ:RAPP) reported earnings of -$0.84 per share for Q3 2026, beating the consensus estimate of -$1.20. The report was announced on Wednesday, November 4, 2026. Rapport Therapeutics Earnings HeadlinesRapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update3 hours ago | finance.yahoo.comRapport Therapeutics (NASDAQ:RAPP) Sees Large Volume Increase After Insider Buying ActivityNovember 4 at 1:21 AM | americanbankingnews.comTrump compared today's market to 1929 not once but twicePresident Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they did. Before a single vote was counted, the IMF flagged markets as increasingly exposed to a sharp correction, Ray Dalio called conditions a classic bubble, and Peter Schiff said a downturn could hit regardless of the outcome.November 4 at 1:00 AM | USA Capital Gold (Ad)Rapport Therapeutics to Participate in Upcoming Investor ConferencesNovember 3 at 7:00 AM | globenewswire.comRapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase ...November 3 at 3:53 AM | finance.yahoo.comRapport Therapeutics (NASDAQ: RAPP) director buys $20.36 million of stock via fundsNovember 3 at 3:13 AM | americanbankingnews.comSee More Rapport Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rapport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapport Therapeutics and other key companies, straight to your email. Email Address About Rapport TherapeuticsRapport Therapeutics (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines. Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy. The candidate is designed to selectively modulate AMPA receptor complexes through their associated proteins. The company is also advancing a broader pipeline of discovery and development programs intended to address additional disorders involving abnormal neuronal signaling, such as pain and psychiatric conditions. Rapport Therapeutics was established in 2018 and is headquartered in Boston, Massachusetts. Its research and development activities are focused on creating medicines for patients with central nervous system diseases, with clinical and commercial opportunities expected to span international markets. The company’s programs remain in development and are subject to the results of clinical trials and regulatory review.View Rapport Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushMarriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestTower Semiconductor's Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?Apple's Earnings Beat Comes With a Catch for Investors Heading Into the Holidays Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)Devon Energy (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
